Efficacy and safety of fedratinib in patients with myelofibrosis previously treated with ruxolitinib (FREEDOM2): results from a multicentre, open-label, randomised, controlled, phase 3 trial

https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(24)00212-6/abstract?utm_campaign=update-lanhae&utm_medium=email&dgcid=hubspot_update_feature_updatealerts_lanhae&_hsenc=p2ANqtz-_EHGNT7kIIXRgtcK4PS0VQh7A_3P1dp42cdi4VZUX6yh7KiYztxOOx5mLWHV5sP8R8IQX_2tn-2uZp55Ne1LLSz4mbpg&_hsmi=328909801&utm_content=328699764&utm_source=hs_email